Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2020-09-08 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
Second Price Monitoring Extn
Share Issue/Capital Change Classification · 99% confidence The document is very short (1908 characters) and contains the header 'RNS Number : 3881Y' and mentions 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content describes a 'Second Price Monitoring Extension' related to trading activity, which is a specific, non-standard regulatory announcement concerning market operations rather than a core financial report (like 10-K, IR, or ER). Since it is a specific regulatory announcement that doesn't fit the other defined categories (like DIRS, DIV, or MANG), the most appropriate classification is the general regulatory fallback category, RNS (Regulatory Filings).
2020-09-08 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1891 characters) and contains the header 'RNS Number : 3865Y'. It announces a 'Price Monitoring Extension' related to trading on the London Stock Exchange. It explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This indicates it is a general regulatory announcement or market notice, not a comprehensive financial report (like 10-K or IR) or a specific corporate action announcement (like DIV or CAP). Given the nature of the announcement (a trading mechanism update provided via RNS) and its brevity, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for miscellaneous regulatory announcements.
2020-09-08 English
Director Award of Share Options
Remuneration Information Classification · 99% confidence The document is a formal announcement released via RNS (Regulatory News Service) on September 4, 2020. The content explicitly details the 'Grant of options' to two Persons Discharging Managerial Responsibilities (PDMRs), Professor Lindy Durrant and Dr Richard Goodfellow, including the number of options and the exercise price. This type of transaction notification, specifically concerning insider dealings or transactions by management, falls under the category of Director's Dealing (DIRS) or potentially a general Regulatory Filing (RNS). Since there is a specific category for 'Director's Dealing' (DIRS) which covers 'Report of personal share transactions by company directors and executives (insider trades)', and this document is a notification of share option grants to PDMRs, DIRS is the most precise classification. It is not a general regulatory announcement (RNS) because DIRS is more specific. It is not a DEF 14A (Remuneration Information) as it concerns specific option grants, not the overall remuneration report.
2020-09-04 English
Funds awarded by Innovate UK for COVID-19 vaccine
Regulatory Filings Classification · 100% confidence The document begins with 'RNS Number : 2594X' and is dated August 27, 2020. It announces that Scancell Holdings plc has secured funding from Innovate UK to progress its COVID-19 vaccine into clinical trials. The text is a formal announcement detailing business developments, funding awards, collaboration details, and quotes from management. It is not a full annual report (10-K), a quarterly report (IR), a transcript (CT), or a proxy statement (DEF 14A/PSI). Since it is a general, material announcement disseminated via the RNS system (London Stock Exchange's news service), and it doesn't fit the specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), the most appropriate general regulatory filing category is RNS (Regulatory Filings). The document length (8698 chars) is substantial enough that it is the primary announcement itself, not just a notice that a report is attached (which would suggest RPA).
2020-08-27 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is identified by the header 'RNS Number' and contains the standard form 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, specifically detailing the percentage of voting rights crossed or reached (15.37%). This directly corresponds to the definition of a Major Shareholding Notification. The presence of the RNS distribution boilerplate confirms it is a regulatory announcement, but the specific content points to MRQ over the general RNS fallback.
2020-08-26 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains fields related to 'Acquisition or disposal of voting rights' and 'Total positions of person(s) subject to the notification obligation', detailing percentage changes (14.45%) and total voting rights. This structure is characteristic of regulatory filings concerning changes in significant share ownership. The RNS Number and reference to the FCA confirm it is a regulatory disclosure. This matches the definition for Major Shareholding Notification (MRQ).
2020-08-25 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.